Paper · 33022971
The Immune Microenvironment in Pancreatic Cancer.
Huber M and 9 others. Int J Mol Sci, 2020. Cited by 208 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. The Immune Microenvironment in Pancreatic Cancer. Papers, record 33022971. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33022971
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics5
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Adenocarcinoma | Major topic |
| Carcinoma, Pancreatic Ductal | Major topic |
| Tumor Microenvironment | Major topic |
| Humans | |
| Immunotherapy |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| KFO325 | Deutsche Forschungsgemeinschaft | PubMed |
Source PubMed
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References239
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 27,494,847 | Preoperative neutrophil-to-lymphocyte ratio and tumor-related factors to predict lymph node metastasis in patients with pancreatic ductal adenocarcinoma (PDAC). | Oncotarget | 2016 | https://conductscience.org/library/papers/27494847 | PubMed |
| 2 | 21,654,544 | The presence of IGHG1 in human pancreatic carcinomas is associated with immune evasion mechanisms. | Pancreas | 2011 | https://conductscience.org/library/papers/21654544 | PubMed |
| 3 | 31,695,760 | Pancreatic stellate cells activated by mutant KRAS-mediated PAI-1 upregulation foster pancreatic cancer progression via IL-8. | Theranostics | 2019 | https://conductscience.org/library/papers/31695760 | PubMed |
| 4 | 29,443,960 | TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. | Nature | 2018 | https://conductscience.org/library/papers/29443960 | PubMed |
| 5 | 32,657,929 | Patient-derived Organoid Pharmacotyping is a Clinically Tractable Strategy for Precision Medicine in Pancreatic Cancer. | Ann Surg | 2020 | https://conductscience.org/library/papers/32657929 | PubMed |
| 6 | 23,007,469 | Protumor and antitumor functions of neutrophil granulocytes. | Semin Immunopathol | 2013 | https://conductscience.org/library/papers/23007469 | PubMed |
| 7 | 31,350,295 | The Tumor Microenvironment Innately Modulates Cancer Progression. | Cancer Res | 2019 | https://conductscience.org/library/papers/31350295 | PubMed |
| 8 | 22,996,369 | Effect of pemetrexed on innate immune killer cells and adaptive immune T cells in subjects with adenocarcinoma of the pancreas. | J Immunother | 2012 | https://conductscience.org/library/papers/22996369 | PubMed |
| 9 | 26,321,679 | Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. | Cell | 2015 | https://conductscience.org/library/papers/26321679 | PubMed |
| 10 | 23,056,397 | Lipocalin2 promotes invasion, tumorigenicity and gemcitabine resistance in pancreatic ductal adenocarcinoma. | PLoS One | 2012 | https://conductscience.org/library/papers/23056397 | PubMed |
1 to 10 of 239
See all 239 referencesCited by164
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 208 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,877,184 | Development of tRNA-based biomarkers for breast cancer: insight from machine learning. | Arch Med Sci | 2026 | https://conductscience.org/library/papers/42877184 | PubMed |
| 42,792,545 | Mechanisms of Immune Cell Dysregulation in Pancreatic Ductal Adenocarcinoma. | Biology (Basel) | 2026 | https://conductscience.org/library/papers/42792545 | PubMed |
| 42,737,789 | Targeting Reactive Species Stress and Nutrient Sensing to Enhance NK-Cell Function: Mechanistic Strategies for Overcoming Pancreatic Cancer Progression and Resistance Through Supplement Therapy. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42737789 | PubMed |
| 42,720,867 | Targeting lncRNA-regulated macrophage polarization: a novel therapeutic strategy for pancreatic ductal adenocarcinoma. | J Physiol Biochem | 2026 | https://conductscience.org/library/papers/42720867 | PubMed |
| 42,648,752 | Ascites reprograms innate lymphoid immune cells in ovarian cancer by promoting ILC2 enrichment and dysfunctional NK-cell states. | J Immunother Cancer | 2026 | https://conductscience.org/library/papers/42648752 | PubMed |
| 42,624,885 | Tumor slice cultures enable rapid ex vivo profiling of patient-specific drug sensitivity in pancreatic ductal adenocarcinoma. | NPJ Precis Oncol | 2026 | https://conductscience.org/library/papers/42624885 | PubMed |
| 42,553,398 | Targeting stroma-mediated T-cell exclusion and functional exhaustion in pancreatic ductal adenocarcinoma through CXCR4 and PD-1 blockade. | Front Immunol | 2026 | https://conductscience.org/library/papers/42553398 | PubMed |
| 42,332,796 | Pregabalin enhances the proliferative potential of pancreatic cancer in vitro but not in mice with pancreatic cancer. | BMC Pharmacol Toxicol | 2026 | https://conductscience.org/library/papers/42332796 | PubMed |
| 42,265,391 | Characterizing pancreatic cancer-associated fibroblast heterogeneity in vascular microphysiological systems. | Angiogenesis | 2026 | https://conductscience.org/library/papers/42265391 | PubMed |
| 42,233,178 | High-Intensity Interval Training Boosts Immune Cells in Advanced Cancer Patients and Healthy Controls: Implications for Cancer Care. | Cancer Med | 2026 | https://conductscience.org/library/papers/42233178 | PubMed |
1 to 10 of 164
See all 164 cited byGenes119
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ACTA2 | 59 | PubTator's text mining | https://conductscience.org/library/genes/59 | NCBI Gene |
| AGER | 177 | PubTator's text mining | https://conductscience.org/library/genes/177 | NCBI Gene |
| AKT1 | 207 | PubTator's text mining | https://conductscience.org/library/genes/207 | NCBI Gene |
| ALDH1A1 | 216 | PubTator's text mining | https://conductscience.org/library/genes/216 | NCBI Gene |
| ANPEP | 290 | PubTator's text mining | https://conductscience.org/library/genes/290 | NCBI Gene |
| ARG1 | 383 | PubTator's text mining | https://conductscience.org/library/genes/383 | NCBI Gene |
| BTK | 695 | PubTator's text mining | https://conductscience.org/library/genes/695 | NCBI Gene |
| CCL13 | 6,357 | PubTator's text mining | https://conductscience.org/library/genes/6357 | NCBI Gene |
| CCL18 | 6,362 | PubTator's text mining | https://conductscience.org/library/genes/6362 | NCBI Gene |
| CCL19 | 6,363 | PubTator's text mining | https://conductscience.org/library/genes/6363 | NCBI Gene |
1 to 10 of 119
See all 119 genesDrugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/33022971
GET https://conductscience.org/api/papers/v1/33022971/references?page=2